Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I think that the guidance for a loss of $10-15MM per quarter (not the $50MM stated in the seekingalpha summary) may be higher than some thought would happen.

You’re probably right; however, I’m much more interested in the guidance for cash operating expenses, which didn’t change materially, than the guidance for the GAAP loss. From the transcript:

Previously I’ve given guidance at total operating expenses excluding stock compensation and the royalty payable to MIT and net collaborate revenues would be between $22 million and $28 million per quarter for 2012. Let me illustrate how I get that number for the first quarter of 2012. Operating expenses totaled $29.5 million that amount less stock-based compensation were $3.3 million less the MIT royalty of $0.4 million and net collaborative reimbursement revenue of $1.1 million equaled $24.7 million for the first quarter… I’m still expecting to be within that guidance for the subsequent quarters of 2012.

p.s. The $50M typo you cited (in place of $15M) for the upper bound of the quarterly GAAP loss is a really bad error. If anyone actually believed such a number, they probably sold already, LOL.